Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Acquisitions & Divestments (2020 - 2025)

Historic Change in Acquisitions & Divestments for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $97.8 million.

  • Relay Therapeutics' Change in Acquisitions & Divestments fell 2974.14% to $97.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.8 million, marking a year-over-year decrease of 5017.85%. This contributed to the annual value of $611.6 million for FY2024, which is 552.11% down from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Change in Acquisitions & Divestments is $97.8 million, which was down 2974.14% from $84.1 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Change in Acquisitions & Divestments ranged from a high of $386.2 million in Q1 2021 and a low of $18.1 million during Q1 2022
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $104.1 million (2024), whereas its average is $125.9 million.
  • Per our database at Business Quant, Relay Therapeutics' Change in Acquisitions & Divestments tumbled by 9531.3% in 2022 and then surged by 86709.39% in 2023.
  • Over the past 5 years, Relay Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $35.2 million in 2021, then soared by 419.21% to $183.0 million in 2022, then rose by 7.43% to $196.6 million in 2023, then tumbled by 47.07% to $104.1 million in 2024, then dropped by 6.03% to $97.8 million in 2025.
  • Its last three reported values are $97.8 million in Q3 2025, $84.1 million for Q2 2025, and $64.8 million during Q1 2025.